Ernesto Isman
Psychiatric/Mental Health · Las Vegas, NVNPI 1326535683
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 26.7% of the total. Reporting peaked in 2023 at $2,051 and has fallen 94.1% since, to $122 in 2025. Among psychiatric/mental health clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$519
- Otsuka America Pharmaceutical, Inc.$470
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$387
- Neurocrine Biosciences, Inc.$309
- Teva Pharmaceuticals USA, Inc.$285
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,147100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 102 | $1,373 |
| Johnson & Johnson | 29 | $519 |
| Otsuka America Pharmaceutical, Inc. | 47 | $470 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $387 |
| Neurocrine Biosciences, Inc. | 20 | $309 |
| Teva Pharmaceuticals USA, Inc. | 19 | $285 |
| Sunovion Pharmaceuticals Inc. | 20 | $278 |
| Alkermes, Inc. | 14 | $274 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $268 |
| Axsome Therapeutics, Inc. | 7 | $167 |
| Almatica Pharma LLC | 7 | $134 |
| Supernus Pharmaceuticals, Inc. | 8 | $128 |
| Corium, LLC | 7 | $128 |
| Novo Nordisk | 1 | $122 |
| Bausch Health US, LLC | 4 | $76 |
| Idorsia Pharmaceuticals US Inc | 4 | $66 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Lundbeck LLC | 2 | $39 |
| Avanir Pharmaceuticals, Inc. | 2 | $33 |
| Eisai Inc. | 1 | $21 |
| Gilead | 1 | $16 |
| Bioxcel Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,151 in reported general payments places this provider in the 90th percentile of 362 psychiatric/mental health providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 17 | $4,413 |
| Quetiapine Fumarate | 47 | $1,116 |
| Trazodone Hcl | 30 | $1,052 |
| Divalproex Sodium | 24 | $478 |
| Bupropion XlBupropion Hcl | 17 | $374 |
| Alprazolam | 77 | $366 |
| Olanzapine | 14 | $283 |
| Sertraline Hcl | 27 | $260 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $214 |
| Risperidone | 12 | $180 |
| Topiramate | 20 | $161 |
| Clonazepam | 23 | $148 |
| Fluoxetine Hcl | 21 | $104 |
| Escitalopram Oxalate | 12 | $89 |
| Diazepam | 17 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $134 | $26027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 362 psychiatric/mental health providers in Nevada.
Other psychiatric/mental health in Las Vegas
- Michelle GiddingsLas Vegas$131K
- Patrick ApiladoLas Vegas$19K
- Joshua HamiltonLas Vegas$17K
- Sydney EganLas Vegas$14K
- Ma Victoria EscardaLas Vegas$12K
- Carminia SalvacionLas Vegas$12K
- Valentina AkohLas Vegas$12K
- Angela WilsonLas Vegas$11K
- Michael MathisenLas Vegas$10K
- Edina BorosLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.